France
Cellnovo Group, with the slogan "The first connected diabetes management platform," is an innovative medical technology company founded in 2002. The company specializes in diabetes and has developed The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system designed for people with type 1 diabetes. The system comprises a compact, intuitive, and entirely connected micro-pump for insulin delivery that communicates wirelessly with a locked-down Android phone, providing quality and responsiveness akin to consumer-grade smartphones while maintaining the high level of security of a medical-grade device. This unique device allows for optimal diabetes management, ensuring freedom of movement and peace of mind for patients and enabling continuous real-time monitoring of the patient’s condition by family members and healthcare professionals.
The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece, and Cyprus. It has a clearly-defined expansion strategy to accelerate product commercialization in Europe, the United States, and Asia, and to increase production capacity to meet the high demand. For more information, visit www.cellnovo.com.
The company secured a €20.00M Post-IPO Debt investment on 10 July 2017, with the investment coming from the European Investment Bank.
Cellnovo Group operates in the Biotechnology, Health Care, and Medical Devices industries, with its headquarters located in France.
Valeritas